NCT05451173View on ClinicalTrials.gov

Combining ICI With SBRT or HypoFrx-RT for ES NSCLC

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

83

Participants

Timeline

Start Date

October 9, 2023

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Non-small Cell Lung CancerNon-small Cell CarcinomaNon-small Cell Lung Cancer Stage INon-small Cell Lung Cancer Stage IINon-small Cell Lung Cancer Stage III
Interventions
RADIATION

Stereotactic body radiotherapy

An ablative dose of radiation is delivered to the primary tumor target over 1-2 week.

RADIATION

Hypofractionated radiotherapy

Hypofractionated radiotherapy is delivered to the primary tumor and any involved lymph node target(s) over 3 weeks.

DRUG

Durvalumab

an anti-PD-(L)1 immune checkpoint inhibitor is administered concurrently and adjuvantly with radiotherapy.

Trial Locations (1)

100053

Capital Medical University Xuanwu Hospital, Beijing

All Listed Sponsors
lead

Alexander Chi

OTHER

NCT05451173 - Combining ICI With SBRT or HypoFrx-RT for ES NSCLC | Biotech Hunter | Biotech Hunter